Defence Therapeutics (XCNQ:DTC) Current Accrued Expense : C$1.45 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Defence Therapeutics Current Accrued Expense?

Defence Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2023 was C$1.45 Mil.

Defence Therapeutics's quarterly Current Accrued Expense increased from Mar. 2023 (C$0.18 Mil) to Sep. 2023 (C$0.39 Mil) and increased from Sep. 2023 (C$0.39 Mil) to Dec. 2023 (C$1.45 Mil).

Defence Therapeutics's annual Current Accrued Expense increased from Jun. 2020 (C$0.05 Mil) to Jun. 2021 (C$0.12 Mil) and increased from Jun. 2021 (C$0.12 Mil) to Jun. 2022 (C$1.11 Mil).

Defence Therapeutics Current Accrued Expense Historical Data

The historical data trend for Defence Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Defence Therapeutics Current Accrued Expense Chart

Defence Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Current Accrued Expense

0.05

0.12

1.11

Defence Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Sep23	Dec23
Current Accrued Expense	Get a 7-Day Free Trial										1.23	0.83	0.18	0.39	1.45

Defence Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

Defence Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of Defence Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Defence Therapeutics (XCNQ:DTC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Defence Therapeutics Inc (XCNQ:DTC) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

DTCFF:USA DTC:Germany

Address

200 Burrard Street, Suite 1680, Vancouver, BC, CAN, V6C3L6

Website

https://www.defencetherapeutics.com

Defence Therapeutics Inc is engaged in the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The Company has one operating segment, being research and development.

Executives

Sarkis Meterissian

Director